Genaco Biomedical Products

Genaco Biomedical Products was a molecular diagnostics company that pioneered the use of multiplexed PCR for infectious disease testing. The company's proprietary platform, Target Enriched Multiplex PCR (Tem-PCR), allowed for the simultaneous identification of dozens of pathogens from a single patient sample. This technology significantly improved the speed and accuracy of diagnosing complex infections, such as those found in respiratory disease and sepsis. In 2006, Genaco was acquired by Qiagen for approximately $40 million to enhance Qiagen's molecular diagnostic portfolio. Following the acquisition, Genaco's technology was integrated into Qiagen's global diagnostic offerings, particularly in the area of hospital-acquired infections.